Isogenic cell lines differing only in the expression of the protein of interest provide the ideal platform for cell-based screening. However, related natural lines differentially expressing the therapeutic target of choice are rare. Here the authors report a strategy for drug screening employing isogenic human cell lines in which the expression of the target protein is regulated by a gene-specific engineered zinc-finger protein (ZFP) transcription factor (TF). To demonstrate this approach, a ZFP TF activator of the human parathyroid hormone receptor 1 (PTHR1) gene was identified and introduced into HEK293 cells (negative for PTHR1). Following induction of ZFP TF expression, this cell line produced functional PTHR1 protein, resulting in a robust and ligand-specific cyclic adenosine monophosphate (cAMP) response. Reciprocally, the natural expression of PTHR1 observed in SAOS2 cells was dramatically reduced by the introduction of the appropriate PTHR1-specific ZFP TF repressor. Moreover, this ZFP-driven PTHR1 repression selectively eliminated the functional cAMP response invoked by known ligands of PTHR1. These data establish ZFP TF-generated isogenic lines as a general approach for the identification of therapeutic agents specific for the target gene of interest. (Journal of Biomolecular Screening 2005:304-313) 
INTRODUCTION

T
ISSUE CULTURE CELL-BASED SCREENS provide high-throughput assays for the discovery and validation of new therapeutic agents for the treatment of diverse disease. However, the quality of data generated by such cell-based assays is dependent on the nature of the control cells. In the field of G protein-coupled receptors (GPCRs), for example, the ability to differentiate between targetspecific cyclic adenosine monophosphate (cAMP) accumulation and general and/or off-target effects that lead to an indistinguishable functional effect is of material value to the drug discovery process. Isogenic lines differentially expressing only the target gene of interest provide the ideal screening platform; however, such lines are essentially nonexistent in nature.
To address this issue, we have developed a strategy for drug screening employing isogenic human cell lines in which the expression of the target protein is regulated by a gene-specific engineered zinc-finger protein (ZFP) transcription factor (TF). ZFP TFs have been employed in the regulation of many human genes, [1] [2] [3] [4] [5] including GPCRs. 6 Moreover, the regulation of gene expression by ZFP TFs can occur with single-gene specificity genome wide. 7 By placing the expression of the ZFP TF under the control of an inducible system, an isogenic clone can be created in which the expression of the target gene of interest is determined by the presence or absence of the gene-specific ZFP TF. These isogenic lines can then be used in parallel to screen for therapeutic compounds with the desired specificity for the gene target.
To demonstrate this approach, we chose to develop isogenic cell lines expressing the human GPCR parathyroid hormone receptor 1 (PTHR1). PTHR1 plays important roles in regulating serum calcium homeostasis and bone metabolism by mediating the action of parathyroid hormone (PTH) and PTH-related protein. A PTHR1 agonist called teriparatide PTH , or Forteo™, was approved by the Food and Drug Administration in 2002 for the treatment of osteoporosis and repair of fractures. 8 A PTHR1-specific antagonist may be of therapeutic utility in the treatment of hyperparathyroidism 9 and/or humoral hypercalcemia of malignancy. 10 Using PTHR1 as the gene target, we show that ZFP TFbased cell lines provide a platform for high-quality, robust assays capable of differentiating between receptor-specific and off-target ligand-induced functional effects.
EXPERIMENTAL PROCEDURES
Cell culture
Human embryonic kidney cells (HEK 293), HeLa, Hep3B, U2OS, and SAOS2 were obtained from ATCC and cultured in Dulbecco's modified Eagle's medium supplemented with 10% tetracycline-free fetal bovine serum in a 5% CO 2 incubator at 37°C. T-REx™-293 cell line was obtained from Invitrogen Corporation (Carlsbad, CA) and cultured in the same medium supplemented with 5 µg/ml of blasticidin S (also from Invitrogen Corporation).
Reagents and media
VIP was obtained from Bachem (Torrance, CA); forskolin from Sigma (St. Louis, MO); TIP 
Assembly and construction of ZFPs
Genes encoding the designed zinc-finger domains were assembled, cloned using PCR, and their binding affinity assessed using gel-shift assays as described previously. 11 For activation studies, the zinc-finger domains were fused with the herpes simplex virus VP16 activation domain (amino acid residues 413-490, Genbank accession #P06492) 12 or the human NF-kB transcription factor p65 subunit (amino acids 288-551). For repression studies, the zinc-finger domains were fused with the Kruppel-associated box (KRAB) repression domain from the human protein KOX1 13 or the N-terminal amino acids 1-231 of the transforming growth factor β-inducible early gene (TIEG). 14, 15 All ZFP TF fusion constructs also contained an N-terminal nuclear localization signal (Pro-Lys-Lys-Lys-Arg-Lys-Val) from SV40 large T antigen and a C-terminal FLAG peptide (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys). They were cloned into the pcDNA3 mammalian expression vector (Invitrogen Corporation), and their expression was driven by a cytomegalovirus promoter.
Quantitative RT-PCR analysis of PTHR1 gene expression by transient transfections
HEK293 cells were seeded in 24-well plates at a density of 160,000 cells/well 24 h before transfection. Plasmids encoding ZFP-VP16 fusions were transfected into the cells via LipofectAMINE 2000 reagent (Gibco-BRL, Gaithersburg, MD) according to the manufacturer's recommendations. Forty-eight hours after transfection, the cells were harvested and assayed for the expression of PTHR1 and GADPH by real-time quantitative reverse transcriptase RT-PCR using Taqman chemistry. Total RNA was prepared using the RNeasy total RNA isolation kit with in-column DNase treatment (Qiagen Inc., Valencia, CA). Taqman was performed on an ABI 7700 SDS machine (PerkinElmer Life Sciences, Wellesley, MA) and normalized to GAPDH levels as described previously. 11 The primers and probes used for quantitative RT-PCR analysis of PTHR1 mRNA levels are shown in Table 1 .
Assay for ZFP binding affinity
The ZFP-maltose-binding protein (MBP) fusions were purified, and electro-mobility shift assays were performed essentially as described. 16 Briefly, the purified ZFP proteins were incubated with radiolabeled oligonucleotide probes in binding buffer that contained 10 mM Tris, 100 mM KCl, 1 mM MgCl 2 , 10 mM DTT, 0.01 mM ZnCl 2 , 10% glycerol, 200 µg/ml bovine serum albumin (BSA), 0.02% IGEPAL CA-630 (Nonidet P-40; Sigma, St. Louis, MO). ZFP concentrations for these studies were determined directly by measuring the DNA-binding activity of each MBP-ZFP fusion proteins using conditions under which binding is essentially stoichiometric.
Generation of stable inducible cell lines
To generate stable Tet-inducible cell lines expressing the ZFP1690-VP16 transcription factor, the coding region from the pCMV-ZFP1690-VP16 vector was subcloned into pcDNA4/TO (Invitrogen) containing a Tet-Operator-controlled CMV promoter. The resulting pTO-ZFP1690-VP16 construct was transfected into the T-REx™-293 cell line using LipofectAMINE 2000 (Life Technologies, Inc.). After 2 weeks of selection in culture medium containing 400 µg/ml Zeocin (Invitrogen), 60 drug-resistant stable clones were isolated and analyzed for PTHR1 induction upon addition of doxycycline (DOX) to the culture medium. For repres- 
sion studies, a Tet-regulated SAOS2 line (TetR-SAOS2) was generated by stably integrating a plasmid encoding the tetracycline repressor (TetR). 17 Then, ZFP1690-TIEG or ZFP1690-KOX, subcloned into the pcDNA4/TO vector (Invitrogen), was transfected into TetR-SAOS2. After 6 weeks of selection in culture medium containing 200 µg/ml Zeocin, pools of drug-resistant cells were collected and analyzed for PTHR1 repression upon addition of DOX.
cAMP accumulation assays
Intracellular cAMP accumulation was determined in subconfluent cell cultures grown in 24-well cell culture plates. After washing the cells with 1 ml DMEM containing 20 mM HEPES and 0.1% BSA, the cells were incubated with various concentrations of the appropriate ligand (10 -11 to 10 -6 M) in the presence of 0.5 mM 3-isobutyl-1-methylxanthine for 15 min at room temperature. The cells were subsequently lysed in 0.1 N HCl, and cAMP content was measured using a direct cAMP immunoassay kit (Sigma, St. Louis, MO). The assay used a rabbit-derived polyclonal antibody to cAMP to competitively bind cAMP in the lysate or cAMP that has been covalently linked to an alkaline phosphatase enzyme. The assay was performed in a 96-well plate precoated with antirabbit IgG antibody and detected using colorometry. In cases requiring high sensitivity, samples were acetylated according to the manufacture's recommendations.
Calcium flux measurement
Cells were seeded into black-walled 96-well poly-D-lysinecoated plates (BD BioSciences) at 30,000 cells/well and grown for 2 days in culture medium in the absence or presence of 2 ng/ml DOX. On the day of the experiment, the media were removed and the cells incubated with 100 µl of culture medium or Hank's Buffered Saline Solution with 20 mM HEPES (fluorescent imaging plate reader buffer) containing Fluo-4 AM (4 µM), pluronic F127 (0.04% in DMSO, both from Molecular Probes, Eugene, OR), and 2.5 mM probenecid (Sigma-Aldrich) for 30 min or 1 h at 37°C. After washing, cells were challenged with agonist PTH(1-34) (Phoenix Pharmaceuticals, Inc., Belmont, CA) at 10 s, and the intracellular Ca 2+ flux was captured using either a Wallac VICTORII instrument equipped with an automatic injector (Perkin-Elmer Life Sciences) measuring the excitation/emission filter pair of 485/535 nM or a fluorescent imaging plate reader (Molecular Devices, Menlo Park, CA) 18 (λ excitation = 488 nM, λ emission = 540 nM).
RESULTS
An engineered ZFP TF activator of the human PTHR1 gene
Three promoters, P1, P2, and P3, control the transcription of the human PTHR1 gene (Fig. 1A) . These promoters drive expression of transcripts with different 5′-untranslated regions, which all encode the same protein. The most proximal promoter, P3, is the most active promoter in both the osteoblast-like cell line SAOS2 [19] [20] [21] and human adult kidney. 22 The sequence of the P3 region was therefore used to design an engineered ZFP TF constructed from an archive of zinc-finger DNA-binding modules. 23 The resulting protein, ZFP1690, recognizes a target site located 246 bp upstream of the ATG start site of translation (Fig. 1A) . The complete amino acid sequence of ZFP1690 is shown in Figure 1B .
The DNA-binding affinity of ZFP1690 for its target sequence was determined using an electro-mobility shift assay in vitro. ZFP1690 bound its target site with an apparent K d of 20 pM (Fig.  1C) . This value is similar to the affinity of SP1 for its consensus binding sequence, which was measured in parallel with ZFP1690 as an apparent K d of 30 pM (Fig. 1C ) in accordance with published values. ZFP1690 is therefore capable of high-affinity DNA binding, similar to that of natural transcription factors.
Next, we determined if ZFP1690 activates the expression of the endogenous PTHR1 gene. The engineered ZFP1690 DNAbinding domain was therefore fused to the transactivation domain of VP16 24 or p65, 25 and the resultant plasmids (ZFP1690-VP16 or ZFP1690-p65) transiently transfected into HEK293, HeLa, Hep3B, U2OS, and SAOS2 cells. These cell lines express measurably different starting levels of endogenous PTHR1 mRNA, with the SAOS2 cell line providing the highest basal level and HEK293 cells the lowest. Both ZFP1690-VP16 and ZFP1690-p65 were able to increase PTHR1 mRNA levels in all cell lines tested, with ZFP1690-VP16 generally being more effective (Fig. 2 ). In contrast, ZFP1690-VP16 did not affect the expression of the related PTHR2 gene, which has a 70% overall amino acid identity to PTHR1 26 but contains no ZFP1690-binding sites in its promoter and expression of which remains undetectable in 293 cells (data not shown), confirming the specificity of this reagent to the intended target. These data identified ZFP1690-VP16 as a powerful and specific activator of the endogenous PTHR1 gene. Importantly, this potent activation was observed despite the very low/undetectable background levels in HEK293 cells, suggesting that HEK293 cells might be a suitable cell line for the creation of ZFP TF isogenic lines.
Regulatable activation of PTHR1 mRNA expression in a stable inducible cell line
As shown above, HEK293 cells display very low levels of PTHR1 mRNA, thus providing for PTHR1 bioassays with low background and potentially high signal-to-background ratios. To eliminate laborious transient transfection procedures, we constructed stable cell lines in which the T-REx system (Invitrogen) provided inducible expression of the ZFP TF. Vectors placing ZFP1690-VP16 expression under the control of a tetracyclineregulatable CMV promoter were constructed and transfected into T-REx-293 cells (stably expressing the TetR protein). A panel of single-cell-derived stable clones was generated and assayed for DOX-dependent activation of PTHR1 mRNA expression (data not ZFP TF-Generated Isogenic Cell Lines for Drug Discovery 19, 21 The locations of the 3 promoters, P1, P2, and P3, are indicated by hooked arrows. Arrowed boxes represent the 5′-untranslated exons U1, U2, U3, U4, and the first coding exon S that encodes the signal sequences. The 1st base of the coding sequence (ATG) is located within exon S and has been designated as coordinate +1. The 2nd coding exon is located more than 10 kbp downstream of exon S. The 5′-untranslated region (5′-UTR) of P1 transcript comprises exon U1 and U2 spliced to exon S. The 5′-UTR of P2 transcript contains exon U3 spliced to exon S. The 5′-UTR of the P3 transcript contains exon U4 and exon S. ZFP1690 has a binding site (5′-GAGGGAGAG-3′) within exon U4 of promoter P3 as indicated. (B) The complete amino acid sequence of the engineered transcription factor ZFP1690-VP16. The engineered ZFP transcription factor contains an N-terminal nuclear localization signal from SV40 (SV40 NLS), a zinc-finger DNA-binding domain containing 3 zinc-finger DNA-binding motifs (fingers 1, 2, and 3), a VP16 transactivation domain, and a C-terminal FLAG antigen tag, as indicated. The key amino acids in each of the recognition helices (position 1 through 6 of the α-helix) are boxed. These amino acids have been shown to be the critical residues involved in contacting the DNA base pairs. 40, 41 (C) Determination of the binding affinity of ZFP1690 for its intended target sequence using an electrophoresis mobility shift assay. Maltose binding protein purified ZFP1690 or SP1 protein (at indicated concentrations in a 3-fold dilution series) were incubated with P shown). The line demonstrating the highest DOX-dependent activation of PTHR1 expression, named HEK293-ZFP1690VP16, was chosen for more detailed expression analysis using a range of DOX concentrations (Fig. 3) . In the absence of DOX, this line expressed very low ZFP TF levels (Fig. 3A) and low to undetectable PTHR1 mRNA levels (Fig. 3B) . Increasing the DOX concentration in the medium led to a concentration-dependent increase in ZFP TF levels (Fig. 3A) and a consequent increase in the expression of the PTHR1 gene (Fig. 3B) . DOX concentrations in excess of 1 ng/ml provided no further increase in either ZFP TF mRNA levels or PTHR1 mRNA levels (Figs. 3A, 3B ). The growth properties of this stable ZFP-expressing line were undistinguishable from those of the parental 293 cells. Using promoter-specific Taqman primer and probe pairs (Table 1) , ZFP1690-VP16 induction was shown to activate the P3 promoter in this HEK293 line (Fig. 3C) . In contrast, ZFP1690-VP16 did not increase expression of the P1 and P2 transcripts (data not shown). Thus, ZFP1690-VP16 induced PTHR1 expression from the targeted P3 promoter and consequently mirrored the behavior of cells naturally expressing PTHR1, such as SAOS2 and human adult kidney cells. Taken together, these data demonstrate that the HEK293-ZFP1690VP16 line permits high-level expression of the PTHR1 gene in a ZFPdependent and DOX-inducible manner.
PTHR1-dependent functional responses in HEK293-ZFP1690VP16
We then determined whether the increase in mRNA levels lead to significant changes in the levels of functional PTHR1 protein. PTHR1 is a class II GPCR 27 transmitting signals in part through the G αs proteins [28] [29] [30] and thereby causing increases in the 2nd messen- 11 The error bars represent standard deviations of 4 sample replicates. (B) Levels of parathyroid hormone receptor 1 (PTHR1) mRNA increase in a DOX-concentration-dependent manner. HEK293-ZFP1690VP16 cells were cultured in medium containing the indicated concentrations of DOX for 48 h. PTHR1 mRNA levels were determined as in Figure 2 . The levels of PTHR1 expression shown are relative to that of untransfected SAOS2 cells (which have a value of 1). (C) Promoter P3 targeted by ZFP1690-VP16 is activated in response to DOX. ZFP1690VP16 cells were cultured in medium containing the indicated concentrations of DOX for 48 h. PTHR1 mRNA levels were determined as in Figure 2 except that promoter P3-specific TaqMan primer and probes sets were employed (Table 1) . ger cAMP. Measurement of cAMP levels is therefore a suitable functional assay in screening for PTHR1-specific agonists and antagonists. To determine whether the elevated PTHR1 mRNA levels observed in response to ZFP TF induction result in functional PTHR1 receptor, we assayed for ligand-dependent cAMP responses. As shown in Figure 4A , PTH(1-34), a fragment of the parathyroid hormone, triggered an accumulation of cAMP in the HEK293 ZFP1690-VP16 cell line in a DOX-dependent manner. The magnitude of the cAMP response generated in the induced HEK293 ZFP stable cell line was comparable to that in previously published studies using the PTHR1 cDNA. 31 At 10 nM of PTH(1-34), the response shown here is the maximal response. Figure 4B shows a PTH(1-34) concentration-dependent cAMP response in the induced HEK293-ZFP1690VP16 cell line. The apparent EC50 generated from these experiments was 1.5 ± 0.3 nM, also similar to previously published results using cDNA. 31, 32 To demonstrate that this cell line shows PTHR1-specific cAMP effects, the cells were challenged by the addition of the ligand VIP, an agonist of the vasoactive intestinal polypeptide receptor (a closely related class II GPCR expressed in HEK293) and the addition of forskolin (a potent activator of adenylate cyclase). Importantly, as shown in Figure 4A , both compounds stimulated cAMP accumulation equally in the presence or absence of ZFP TF (plus/minus DOX), confirming that the DOX and ZFP effects on cAMP were PTHR1 specific.
In addition to stimulating adenylyl cyclase via G αs , ligand activation of PTHR1 also stimulates the Ca 2+ 2nd messenger system via G αq proteins. 33, 34 To further establish the functionality of the PTHR1 receptor generated by the ZFP TF, we employed a 2nd bioassay, testing for a PTHR1-induced calcium flux response. As shown in Figure 4C , addition of the ligand PTH(1-34) triggered a transient increase in fluorescence, indicating a rise in the intracellular Ca 2+ concentration in the DOX-induced HEK293-ZFP1690VP16 cells. This signal was not observed in the absence of DOX, confirming the requirement for activation of the PTHR1 receptor by the ZFP TF. Alternative forms of the ligand including the whole hormone PTH and fragments PTH(1-29) or modified PTH(1-21) also triggered an indistinguishable calcium flux response (Fig. 4D) .
To further test the utility of the ZFP TF-engineered HEK293 cell line for screening, we tested the behavior of this line in response to a known selective high-affinity PTHR1 antagonist, the tuberoinfundibular peptide TIP(7-39). 35 As expected, TIP(7-39) has no detectable agonist activity in the induced HEK293-ZFP1690VP16 cell line (Fig. 5A) . However, in the presence of the PTH(1-34) ligand, TIP(7-39) antagonized PTH-induced cAMP accumulation (Fig. 5A ) in a dose-dependent manner (Fig. 5B) . The apparent IC 50 for TIP(7-39) was 5.0 ± 4.9 nM in multiple experiments. Using the cDNA transfection approach, however, TIP(7-39) has been shown to be a competitive antagonist with an affinity of 150 nM in cAMP assays and 6 nM in competitive binding assays. 35 This discrepancy is likely due to the difference in our approaches to produce the functional PTHR1 protein: endogenous gene activation versus cDNA transfection. In summary, the results described above demonstrate that the isogenic HEK293-ZFP1690 VP16 cell line generated a PTHR1 assay platform capable of delivering a robust response to PTHR1-specific agonists and antagonists measured by 2 different bioassays. Moreover, this platform was capable of differentiating between target-specific and general effects.
Regulatable repression of PTHR1 mRNA expression in a stable inducible cell line using ZFP TF repressors HEK293 cells provided us with the opportunity to use the ZFP TF to generate PTHR1-positive cells from a low to negative cellular background, thus creating an isogenic pair of lines differing only in the expression of the receptor. A 2nd strategy for the generation of isogenic lines for cell-based screening employs the transcriptional repression of the gene target in the background of natural cell lines normally expressing functional levels of the receptor. To validate this gene repression approach, we employed the osteosarcoma cell line SAOS2, which expresses the PTHR1 gene (Fig. 2) . 22, 36 Two ZFP TF repressors of the PTHR1 gene were generated by fusing the ZFP1690 DNA-binding domain to 2 transcriptional repression domains: 1) the KRAB A/B box from the KOX1 protein 7 and 2) a previously characterized domain from the TIEG protein.
14 Vectors placing ZFP1690-TIEG, ZFP1690-KOX, and green fluorescence protein (GFP) under the control of a DOXinducible CMV promoter were transfected into TetR-SAOS2 cells (stably expressing the TetR protein). Following an extended period of drug selection (6 weeks), pools of resistant cells were collected and analyzed for the repression of PTHR1 mRNA levels. As shown in Figure 6A , both TetR-SAOS2 ZFP1690-TIEG pools and TetR-SAOS2 ZFP1690-KOX pools were able to dramatically reduce the expression of PTHR1 by 80% in a DOX-dependent manner. Addition of DOX to the TetR-SAOS2 GFP pool demonstrated that the majority (90%) of the cells expressed GFP, thus confirm- ing that the selection procedure had been successful. As expected, DOX-induced expression of GFP in this cell line did not alter PTHR1 expression levels (Fig. 6A) .
PTHR1-dependent functional responses in TetR-SAOS2 ZFP1690-TIEG
To determine the functional consequences of ZFP-mediated PTHR1 repression, we employed a luciferase reporter containing cAMP response elements (CREs) to monitor the PTH-dependent cAMP response. This reporter-based assay has been used previously to monitor PTHR1 receptor function in SAOS2 (data not shown) and provides an easy-to-measure, high-throughput assay for the study of ligand-dependent cAMP accumulation. As shown in Figure 6B , PTH(1-34) greatly stimulated luciferase activity in the TetR-SAOS2 ZFP1690-TIEG cells in the absence of DOX (i.e., in the presence of normal levels of PTHR1). Following DOXinduced ZFP TF repressor expression, the PTH(1-34)-dependent cAMP response (as measured by the CRE-luciferase reporter assay) was effectively abolished (Fig. 6B) . To address the specificity of ZFP TF action, we determined the cAMP response to VIP using the CRE-luciferase reporter. As shown in Figure 6B , the response of the TetR-SAOS2 ZFP1690-TIEG cells to VIP was unaffected by the presence of DOX. Taken together, these data demonstrate that PTHR1-specific ZFP TF repressors can be employed to shut down target gene expression and ablate the cAMP accumulation specific to the presence of the PTHR1 receptor.
DISCUSSION
We present here the use of a novel strategy for drug screening employing isogenic human cell lines in which the expression of the target protein is regulated by a gene-specific engineered ZFP TF. Using the PTHR1 gene as a model system, we show that ZFP TF activators and repressors can be employed to generate cell lines in which the presence of functional receptor is determined by the expression of the ZFP TF. Moreover, we show that both the ZFP TFinduced expression of receptor in a null background and the ZFP TF-driven repression of receptor in a PTHR1-positive cell type generate isogenic lines with proven ability to differentiate between target-specific and nonspecific functional effects. These data establish ZFP TF-generated isogenic lines as a general approach for the identification of therapeutic agents specific for any target gene of interest, including but not limited to GPCRs, nuclear hormone receptors, ion channels, and membrane receptor kinases. In addition to the creation of optimal control cell lines, the direct regulation of the appropriate endogenous gene has 2 indirect benefits over the cDNA transfection approaches. First, the physiological level of gene activation supported by ZFP TFs in turn generates functional assays more representative of the target tissue. 6, 16 Although the cDNA transfection methods generate more proteins in general, massive protein overproduction using the cDNA approach is sometimes not desired. In the case of PTHR1, massive overexpression can induce apoptosis upon ligand binding. 37 In addition, assays featuring endogenous gene activation may lead to more meaningful pharmacological data. The cDNA approach sometimes generates misleading information. 35 Second, by acting directly on the endogenous gene, the ZFP TF platform obviates the need for cDNA cloning or isolation, thus providing a workaround to cDNA patents.
In summary, the ability of ZFP TFs to both up-and downregulate target genes has proven valuable for the elucidation of gene function, 38 the dissection of signaling pathways, 39 and the creation of agents with the potential for direct therapeutic intervention. 16 The cell-based screening tool described here extends this utility to provide a robust method for rapid discovery of gene-specific therapeutic compounds.
